SCHEDULE 13G: Deep Track Capital Discloses 5.24% Stake in Structure Therapeutics Inc.
Beneficial Ownership Report
Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has disclosed a beneficial ownership of 5.24% in Structure Therapeutics Inc.'s Ordinary Shares.
Summary
- Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin (collectively, the "Reporting Persons") have filed a Schedule 13G, indicating beneficial ownership in Structure Therapeutics Inc.
- The Reporting Persons collectively beneficially own 9,000,000 Ordinary Shares of Structure Therapeutics Inc.
- This ownership represents 5.24% of the total outstanding Ordinary Shares of Structure Therapeutics Inc.
- The shares beneficially owned include 3,000,000 American Depositary Shares (ADS), with each ADS convertible into three ordinary shares.
- The calculation of the percentage of class is based on 171,782,018 Ordinary Shares outstanding as of October 31, 2024, as reported in the issuer's 10-Q filed on November 13, 2024.
- The filing indicates shared voting and dispositive power over all 9,000,000 shares.
- The filing was made pursuant to Rule 13d-1(b), indicating that Deep Track Capital, LP is an investment adviser.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently lead to a positive or negative sentiment beyond the fact of a significant investment.
Future Outlook
NA
Industry Context
This filing indicates a significant investment by a specialized biotechnology fund in Structure Therapeutics Inc., a company operating in the biotechnology sector. Such investments by institutional players can signal confidence in the company's prospects within the industry.
Stakeholder Impact
- Shareholders: The disclosure of a new significant institutional investor holding over 5% of the company's shares may be viewed positively, potentially increasing investor confidence and liquidity.
Key Dates
| Date | Description |
|---|---|
| 2024-10-31 | Date as of which 171,782,018 Ordinary Shares were outstanding, according to the issuer's 10-Q. |
| 2024-11-13 | Date Structure Therapeutics Inc. filed its 10-Q with the SEC, reporting outstanding shares. |
| 2025-01-06 | Date of event which required the filing of this statement. |
| 2025-01-13 | Date the Schedule 13G statement was signed and filed. |
Keywords
Structure Therapeutics Inc., Deep Track Capital, Deep Track Biotechnology Master Fund, David Kroin, Schedule 13G, Beneficial Ownership, Ordinary Shares, Biotechnology, Investment Adviser, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.